Title
Type 2 Innate Lymphoid Cells in Allergic Disease.

Permalink
https://escholarship.org/uc/item/7q66s65z

Journal
Current immunology reviews, 9(4)

ISSN
1573-3955

Authors
Lund, Sean
Walford, Hannah H
Doherty, Taylor A

Publication Date
2013-11-01

DOI
10.2174/1573395510666140304235916

Peer reviewed
Type 2 Innate Lymphoid Cells in Allergic Disease

Sean Lund1, Hannah H. Walford1,2 and Taylor A. Doherty*,1

1Department of Medicine, University of California, La Jolla, CA, USA
2Rady’s Children’s Hospital of San Diego, Division of Rheumatology, Allergy and Immunology, San Diego, CA, USA

Abstract: Type II innate lymphoid cells (ILC2) are a novel population of lineage-negative cells that produce high levels of Th2 cytokines IL-5 and IL-13. ILC2 are found in human respiratory and gastrointestinal tissue as well as in skin. Studies from mouse models of asthma and atopic dermatitis suggest a role for ILC2 in promoting allergic inflammation. The epithelial cytokines IL-25, IL-33, and TSLP, as well as the lipid mediator leukotriene D4, have been shown to potently activate ILC2 under specific conditions and supporting the notion that many separate pathways in allergic disease may result in stimulation of ILC2. Ongoing investigations are required to better characterize the relative contribution of ILC2 in allergic inflammation as well as mechanisms by which other cell types including conventional T cells regulate ILC2 survival, proliferation, and cytokine production. Importantly, therapeutic strategies to target ILC2 may reduce allergic inflammation in afflicted individuals. This review summarizes the development, surface marker profile, cytokine production, and upstream regulation of ILC2, and focuses on the role of ILC2 in common allergic diseases.

Keywords: Allergy, asthma, atopic dermatitis, ILC2, nasal polyps, Type 2 innate lymphoid cells.

INTRODUCTION

Allergic inflammation is characterized by increased Th2 cytokines including IL-4, IL-5, and IL-13 resulting in tissue eosinophilia, epithelial mucus metaplasia, and IgE production [1]. Classically, conventional CD4+ Th2 cells have been considered as the primary regulators of the allergic response through production of Th2 cytokines. However, during the past decade, a novel Th2 cytokine-producing population has been identified resulting in a paradigm shift in our understanding of allergic inflammation. Type 2 innate lymphoid cells (ILC2) were first described in 2001 by Fort et al. as non-B/non-T cells that produced IL-5 and IL-13 in response to IL-25 and expressed MHC class Ihigh and CD11cnull [2]. Further, IL-25 administered to RAG1 knockout mice that lack B or T cells led to eosinophilia and increased tissue IL-5 and IL-13 expression suggesting that a non-B/non-T cell population was active in vivo. A subsequent report showed that an IL-25 responsive non-B/non-T cell population produced IL-5 in the lungs of mice and expressed CD45R, B220, and Thy1 (+/+), but was negative for NK1.1, Ly-6G(GR-1), CD4, CD3, and c-kit [3]. Importantly, mice deficient in NK cells, mast cells, and T/B cells mounted pulmonary eosinophilia after IL-25 administration that was not present in RAG2γc double knockout mice, thus demonstrating the importance of γc cytokines in the development and/or maintenance of this novel population. In 2006, Fallon et al. described the expansion of a similar c-kit+ non-B/non-T population in the context of a helminthic infection [4]. Further, the authors demonstrated that IL-25 was required for expulsion of N. brasiliensis and occurred dependent of B and T cells.

In 2010, three landmark independent studies further characterized the phenotype and function of Th2 cytokine producing non-B/non-T cell populations that are now termed ILC2 by consensus [5-8]. Moro et al. described a lineage-negative c-kit+Sca-1+ lymphoid cell population present in the mesenteric fat of mice that produced large amounts of IL-5 and IL-13 in response to IL-33 and induced intestinal goblet cell hyperplasia after N. brasiliensis infection [7]. The cells were termed natural helper cells (NHC). In the same year, another report showed that a similar non-T cell population termed “nuocytes” was detected in mesenteric lymph nodes (MLN) and small intestines of IL-13 reporter mice stimulated with IL-25 and IL-33 [5]. Nuocytes expanded in vivo after helminth infection in an IL-25 and IL-33 dependent manner and nuocyte IL-13 was required for worm expulsion. The third report similarly described lineage-negative IL-13 producing cells termed innate helper type 2 cells (lh2) that were increased in MLN, spleen, liver, and lung after N. brasiliensis infection and were sufficient to expel worms in the absence of adaptive immunity after stimulation with IL-25 [6]. Collectively, these studies demonstrated that nuocytes, natural helper cells and innate helper type 2 cells (now all termed ILC2) are novel Th2 cytokine producing cells and set the stage for a potential role for ILC2 in allergic disease. In this review, we will highlight ILC2 development, regulation, cytokine production, and potential roles in allergic diseases both in humans and in mice.

ILC2 DEVELOPMENT

ILC2s originate from common lymphoid progenitors (CLPs) that were previously known to require inhibitor of DNA binding 2 (Id2), Notch, and the IL-7 receptor (IL-7R) that signals through the common γ chain (γc) [7, 9-11]. One report specifically showed that bone marrow natural helper cells develop from common lymphoid progenitors (CLPs)
and not from either myeloid or erythroid progenitors, confirming that ILC2s are of lymphoid origin [9]. Additionally, Moro et al. found a near complete absence of c-kit+ Sca-1+ natural helper cells in Id2 knockout mice consistent with the requirement of Id2 for innate lymphoid cell development [7]. Several studies have since shown that mice deficient in either IL-7 or its receptor lack ILC2 [7, 12, 13].

Notch signaling was previously shown to be required for in vitro differentiation from CLPs into nuocytes and a recent study demonstrated that high levels of Notch signaling trigger ILC2 differentiation from human uncommitted thymic progenitor cells, and lower levels trigger a T cell program of differentiation [14, 15]. T cell factor 1 (TCF-1) is downstream of Notch signaling and was recently shown to be critical for the development of functional ILC2 [16]. In addition to Notch signaling, the transcription factor RORα was also shown to be required for nuocyte differentiation in vitro and for IL-25-induced nuocyte expansion and goblet cell hyperplasia in vivo [14]. Another report substantiated the requirement of RORα for natural helper cell development and notably showed that other ILC and Th2 cell responses were normal, suggesting more specific ILC2 regulation by RORα [17].

Recently, the master Th2 cytokine transcription factor GATA3 has been shown to play a critical role in human and mouse ILC2 development and function [18-20]. In a recent report, GATA3-deficient CLPs did not express RORα or Id2 mRNA and were not capable of producing IL-5 or IL-13 [19]. The transcription factor Gfi1 contributes to Th2 cell development by stabilizing GATA3 and a recent report evaluated the role of Gfi1 in ILC2 development and function [21, 22]. Interestingly, loss of Gfi1 led to reduced ILC2 responsiveness to IL-33 and Gfi1 knockout ILC2 expressed low levels of IL-5, but co-expressed IL-13 and IL-17, suggesting that Gfi1 contributes to the type 2 effector program of ILC2 [22]. Taken together, the development of ILC2 from CLPs depends on GATA3-induced Id2 and RORα, in addition to Notch and IL-7R signaling.

ILC2 SURFACE MARKERS

Initial studies reported that the common surface markers expressed (though to variable levels) by Ih2, nuocytes, and NHC included CD45, Thy1.2, CD44, CD69, and c-kit (Table 1). Distinct phenotypic differences between these three populations exist in expression of Sca-1, T1/ST2 and IL-7Rα. These differences may reflect tissue and condition specific variations in ILC2 phenotype and/or methods of ILC2 identification. Regardless of some phenotypic distinctions, consensus has been reached to identify Ih2, nuocytes, and natural helper cells as ILC2 [8]. Human ILC2 were initially detected in the gastrointestinal tract, lung, nasal polytissue and peripheral blood and are defined by expression of the prostaglandin D2 (PGD2) receptor CRTH2 [23].

Notably, a separate lineage-negative population of cells termed multipotent progenitor type 2 cells (MPP2) was discovered in IL-4 reporter mice stimulated with IL-25 and was initially included along with other innate Th2 cytokine producing cells [24]. However, further work has now clearly shown that ILC2 are distinct from MPP2 that can differentiate into basophils, macrophages, and mast cells [25]. Interestingly, simultaneous activation of both ILC2 and MPP2 occurs after IL-25 exposure in vivo demonstrating complex parallel pathways that may contribute to type 2 inflammation.

UPSTREAM REGULATION OF ILC2

ILC2s both respond to and are activated by a number of different molecules, including cytokines and other inflammatory mediators (Fig. 1). Initial reports demonstrated that ILC2 were activated by IL-25 and IL-33 leading to robust Th2 cytokine production (2-7). IL-25 (IL-17E) is a member of the IL-17 family and binds specifically to the heterodimer of IL-17RB and IL-17RA leading to activation of MAP kinase and NF-kB pathways [26]. IL-25 is secreted by many cell types including Th2 cells, eosinophils as well as epithelial cells [26]. IL-33 is released by the airway epithelium and lung macrophages, and binds to T1/ST2, a heterodimer of ST2 and the IL-1 receptor accessory protein (T1) [27-29]. IL-33 exists in a biologically active pro-form as well as a processed cleaved protein. The binding of IL-33 to T1/ST2 leads to p38 MAPK as well as NF-kB signaling [27]. Both IL-25 and IL-33 are induced in allergic lung inflammation and thus are available for potent ILC2 stimulation [13, 29-32]. One report recently demonstrated that IL-33 is more potent than IL-25 to activate IL-13 producing ILC2 and induce airway hyperresponsiveness in allergen challenged mice [33]. Consistent with this, another report showed that ST2 knockout mice, but not IL-17RB

| Subtype | Tissue Localization | Surface Markers | References |
|---------|---------------------|-----------------|------------|
| Human | ILC2 | nasal polyps, sinus epithelium, peripheral blood, lung, gastrointestinal tract | CD7, CD25, CD62L, CD127, CD161, CRTH2, ST2 (IL-33R), ALX, CMKLR1, NKG2D, c-kit, DR3 | [13, 18, 23, 39, 45] |
| NHC | bone marrow, liver, lung, mesenteric lymph node, peritoneum, spleen | CD25, CD122 | [6] |
| Nuocyte | bone marrow, lung, mesenteric lymph node, spleen | CD25, CD27, CD38, IL-7Rα, Sca-1, T1/ST2, GITR | [7, 9, 13, 37] |
| Mouse | Ih2, NHC, Nuocyte shared markers | CD45, Thy1.2 (CD90.2), CD44, CD69, c-kit | [5-7, 25] |
Fig. (1). Interactions and functions of airway ILC2. ILC2 respond to epithelial cytokines TSLP, IL-33, and IL-25 and in turn produce Th2 cytokines. Additional ILC2 stimulation may occur from PGD2 and leukotriene D4 produced by mast cells and macrophages, and inhibitory signals from lipoxin A4. TL1A is also produced by dendritic cells and macrophages and can activate ILC2. ILC2 IL-5 production stimulates eosinophil activation and survival, whereas ILC2 IL-13 induces airway hyperresponsiveness, and along with IL-9, promotes mucus production. ILC2 IL-4 may contribute to Th2 cell differentiation and amphiregulin secreted by ILC2 binds to EGFR in the airway epithelium to induce repair responses.

knockout mice, were impaired in allergic sensitization to house dust mite [34]. Though IL-33 appears to play a dominant role in some settings, both IL-33 and IL-25 induce different routes of activation of ILC2s that may depend on the availability of these cytokines from different cell types.

Aside from IL-25 and IL-33, more recent work has identified other mediators of ILC2 activation. TSLP is an epithelial cytokine induced in allergic inflammation and previously shown to induce conventional Th2 cell priming through the costimulatory action of OX40 ligand expressed on dendritic cells [35, 36]. Subsequently, a role for TSLP in activation of ILC2 was demonstrated as purified human peripheral blood and nasal polyp ILC2 cultured with TSLP and IL-33 displayed enhanced IL-4, IL-5, and IL-13 production above IL-33 alone [18]. TSLP has also been shown to activate mouse lung and skin ILC2 [37, 38].

Interestingly, recent reports have shown that a number of eicosanoids, arachidonic acid-derived lipid mediators, that are elevated in allergic inflammation can either directly stimulate or inhibit ILC2 [39-41]. Barnig et al. demonstrated that PGD2 (binds to CRTH2 expressed on human ILC2) potentiates peripheral blood ILC2 IL-13 production above IL-2, IL-25, and IL-33 in vitro [39]. Furthermore, this effect was lost upon the addition of lipoxin A4 (LXA4) suggesting that LXA4 has an inhibitory effect on human ILC2. In addition to PGD2 stimulation of ILC2 cytokine production, we have also detected increased human peripheral blood ILC2 chemotaxis in response to PGD2 [42]. Further, we have shown that mouse lung ILC2 express the cysteinyl leukotriene 1 receptor (CysLT1R) that is preferentially activated by leukotriene D4 [40]. Leukotriene D4 potently induced calcium influx and Th2 cytokine production from purified lung ILC2 in vitro, and potentiated ILC2 proliferation and lung eosinophilia in RAG2 knockout mice. The eicosanoid molecules including prostaglandins, leukotrienes and lipoxins are largely produced by macrophages, mast cells, eosinophils and dendritic cells and thus represent novel pathways through which ILC2 can be activated [41].

The TNF superfamily member TL1A binds to Death receptor 3 (DR3) and signals through TRADD and the intracytoplasmic death domain [43]. TL1A is produced by dendritic cells and macrophages in response to TLR and Fc receptor cross-linking and is also produced by T cells in response to TCR stimulation [44]. TL1A/DR3 costimulation of T cells was previously shown to be required for generation of a Th2 response and development of allergic lung inflammation in OVA models of asthma [44]. Yu et al. have recently reported that TL1A also directly activates ILC2 and synergizes with IL-25 in vivo to promote cytokine production and increase numbers of ILC2s [45]. Further, Dr3-/- mice showed an impaired ability to clear Nippostrongylus brasiliensis infection and had reduced ILC2 levels and lung inflammation compared with WT mice. The activation of ILC2 by TL1A provides new insight into
mechanisms of ILC2 activation as TL1A is available at mucosal sites including the lung and could synergize with known ILC2 activators.

Recently, IL-9 was shown to play a critical role in ILC2 survival [46]. The authors found that IL-9 is an autocrine factor necessary for amphiregulin, IL-5, and IL-13 production, as well as eosinophil recruitment [46]. IL-9R−/− mice had reduced tissue repair responses, and this work further highlights the potential importance of ILC2 in tissue protective roles. The authors hypothesized that the antiapoptotic protein BCL3 could be conferring survival to ILC2 by inhibiting cell apoptosis associated with activation [46].

**ILC2 CYTOKINE PRODUCTION**

ILC2s were initially described to produce high levels of IL-5 and IL-13 and very low levels of IL-4 in response to IL-33 in vitro [5, 7]. Interestingly, this cytokine pattern (high IL-5, IL-13 and low IL-4) may be more related to the effects of IL-33 as conventional T cells stimulated with IL-33 develop into IL-5 producing cells that do not produce IL-4 [47]. Subsequently, studies have shown that ILC2 stimulated with TSLP and leukotriene D4 produce IL-4 suggesting that ILC2, under certain conditions, are a source of IL-4 [18, 40]. Interestingly, lung ILC2 have recently been shown to constitutively produce IL-5 critical to eosinophil homeostasis, though IL-13 production requires IL-25 or IL-33 stimulation [48]. As stated above, ILC2 highly express the master Th2 cytokine transcription factor GATA3 that is required for ILC2 Th2 cytokine production [13, 18-20]. Though conventional Th2 cells and ILC2 share GATA3 expression, ILC2 express GATA3 in the bone marrow suggesting they are primed for Th2 cytokine production without peripheral differentiation [13, 20]. Importantly, a recent study demonstrated that TSLP further enhances GATA3 expression in human ILC2, and thus may be one mechanism of ILC2 Th2 cytokine production induced by TSLP [18].

ILC2 have also been shown to produce IL-6, IL-9, and the EGFR ligand amphiregulin [7, 32, 49, 50]. IL-9 contributes to many features of allergic asthma in animal models including airway eosinophilia and mucus production [51]. Lung ILC2 from mice challenged with the protease allergen papain were found to be a dominant source of IL-9 dependent on IL-2, and ILC2 cultured with IL-9 showed increased production of IL-5, IL-6, and IL-13 [50]. Amphiregulin is produced by ILC2 after airway administration to mice of influenza virus and the fungal allergen Alternaria [32, 49]. In mice receiving influenza virus, ILC2 amphiregulin promoted lung tissue repair suggesting that ILC2 may contribute to both pathogenic and healthy remodeling responses in the lung [49]. Finally, the alternatively activated macrophage enzyme Arginase 1 is constitutively produced by ILC2s though deletion of the Arginase 1 gene does not appear to inhibit cytokine production, proliferation or survival of ILC2s [52]. Overall, these reports suggest that the variable cytokine production by ILC2 during lung responses may play distinct roles depending on the inflammatory context.

**ILC2 LOCALIZATION IN TISSUES**

ILC2 have been found in several different anatomical locations and have been studied in various mouse models of disease (Table 1). Studies in mice have shown ILC2 to be present in lung, skin, mesenteric lymph nodes, bone marrow, liver, spleen, gastrointestinal tract and in mesenteric fat-associated lymphoid clusters [5-7, 9, 28, 38]. Interestingly, lung IL-5 positive ILC2 are localized to the collagen rich regions of the conducting airways, but not in alveolar spaces [48]. In humans, ILC2s have been found in nasal polyps, sinus epithelium, peripheral blood, lung, and in the gastrointestinal tract [18, 23, 49]. Thus, the extensive distribution of ILC2 in tissues suggests that ILC2 may contribute to many organ specific type 2 inflammatory responses.

**ROLES OF ILC2 IN ALLERGIC DISEASE**

The roles and regulation of ILC2 in the following allergic diseases are summarized in Table 2.

**ILC2 in Mouse Models of Asthma**

Mouse models of asthma induced by allergens or viruses are characterized by features found in human asthma including airway hyperresponsiveness, peribronchial inflammation, epithelial mucus production and airway remodeling. Several studies have demonstrated the importance of ILC2s in different mouse models and are also reviewed elsewhere [53, 54]. ILC2 have been shown to contribute to type 2 lung inflammatory responses and airway hyperresponsiveness (AHR) in mice infected with influenza virus and after challenge with multiple allergens including Alternaria, papain, house dust mite and OVA [12, 13, 28, 37, 55, 56]. The initial report by Chang et al. showed that ILC2 IL-13 production was required for AHR induced by influenza virus as adaptive transfer of wild type ILC2, but not IL-13 knockout ILC2, restored AHR in ILC2 depleted mice [28]. Another report demonstrated that the numbers of IL-5 and IL-13 producing lung ILC2 were shown to be equivalent to conventional cytokine producing Th2 cells in mice challenged with house dust mite [56]. Our group and others have reported that intranasal administration of the fungal allergen Alternaria alternata rapidly induces IL-33, activation of lung ILC2, and airway eosinophilia dependent on IL-33 signaling [12, 32]. Further, we found that ILC2 express receptors for IL-4 and IL-13 and proliferation was impaired in STAT6 deficient mice suggesting either a direct or indirect regulation of ILC2 by the IL-4/IL13/STAT6 axis. A single challenge with Alternaria given to mice also induces rapid cysteinyl leukotriene production dependent on STAT6 that may further regulate ILC2 activation and/or proliferation [40].

Though ILC2 appear to direct pathogenic lung responses in asthma models, there is evidence that ILC2 may promote tissue repair after viral and allergen challenges. In ILC2-depleted RAG-deficient mice infected with influenza, there was significant impairment in post infection epithelial barrier regeneration that was restored upon ILC2 transfer [49]. Importantly, the EGFR ligand amphiregulin was highly produced by ILC2 and was sufficient to induce epithelial repair after ILC2 depletion. In addition to influenza virus, Alternaria alternata intranasal challenges to induce ILC2 production of amphiregulin and upregulate the amphiregulin receptor EGFR supporting a role for ILC2 in tissue repair post allergen challenge as well [13]. Thus, ILC2 may have
both harmful as well as beneficial effects in lung inflammation. ILC2 are activated both by epithelial-derived cytokines such as IL-25, IL-33, and TSLP as well as leukotrienes found elevated in asthma, and yet ILC2 also produce amphiregulin, an important tissue repair mediator. Airway ILC2 responses and upstream mediators are shown in Fig. (1). Further research is needed to elucidate the relative contribution of ILC2 during development and resolution of inflammatory responses as well as tissue repair.

ILC2 in Human Asthma

ILC2 have not been studied extensively in human asthma, though ILC2 as well as upstream cytokines and mediators including IL-33, leukotrienes, and PGD2 have been detected in human lungs [39, 49, 57, 58]. In 2001, a report showed that human asthmatics had increased serum T1/ST2 receptor during acute exacerbation [59]. Subsequent studies have shown increased levels of IL-25, IL-33, and TSLP in patients with asthma [58, 60, 61] that all have the potential to active ILC2. In 2009, a landmark study reported the presence of a CD34+ non-B/non-T lymphocyte population found in asthmatic sputum that produced IL-5 and IL-13 in response to inhalational allergen challenge [62]. Whether or not these cells are the same as CRTH2-expressing ILC2 found later in human lungs is not clear. Taken together, these studies suggest that ILC2 may play a significant role in human asthma especially given the heterogeneity of asthma triggers apart from allergens including tobacco smoke, viruses, and ozone that could activate innate pathways.

ILC2 in Chronic Rhinosinusitis

Chronic rhinosinusitis (CRS) is an inflammatory condition involving the mucosal lining of the nose and paranasal sinuses, estimated to affect 2% to 5% of the adult general population and is often associated with asthma, aspirin sensitivity, cystic fibrosis and allergic disease [63]. Chronic rhinosinusitis with nasal polyps (CRSwNP) represents a distinct disease entity from chronic rhinosinusitis without nasal polyps (CRSsNP). In 2011, ILC2 were first reported to be enriched in nasal polyps suggesting a potential role for these cells in CRSwNP [23]. A subsequent study identified an increased percentage of ILC2 in inflamed sinonasal mucosa (not polyp tissue) from patients with CRSwNP as compared to CRSsNP [64]. Further work has shown that ILC2 from nasal polyps produce IL-13 in a GATA3-dependent manner after culture with IL-2, IL-33 and TSLP [18]. Additionally, epithelial cells from patients with CRSwNP show high levels of mediators that regulate ILC2 including TSLP and IL-33[64, 65]. Further, TSLP enhanced the level of ILC2 GATA3 expression that may account for increased cytokine production [18]. Interestingly, ectopic expression of GATA3 by retrovirus of LinCD127 CD117 NKp44 CRTH2 cells resulted in the induction of surface CRTH2, T1/ST2, and TSLP-R as well as IL-13 production in response to TSLP and IL-33. This work critically demonstrates the role of GATA3 in directing human ILC2 programming.

A recent consensus report suggests the importance of endotypes within CRSwNP patients defined by histopathologic features, cytokine profiles and presence of different cell types [66]. Though a large portion of nasal polyps contain high numbers of eosinophils and correlate with elevated Th2 cytokine levels, there is increasing recognition that polyps have varying cellular predominance due to distinct pathogenic mechanisms [67]. We have recently found that eosinophilic nasal polyps from allergic individuals have a higher percentage of GATA3-expressing ILC2 as compared to non-eosinophilic nasal polyps from individuals with unknown allergic status (unpublished data), thus further implicating ILC2 in the development of eosinophilic CRSwNP.

ILC2 in Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin condition associated with skin barrier disruption, eosinophilic infiltration and high serum IgE levels. Recently, studies have

---

**Table 2. Regulation and Function of ILC2 in Mouse Models and Human Allergic Disease**

| Allergic Disease   | ILC2 Upstream Regulation | ILC2 Function | Role of ILC2 in Disease | References |
|--------------------|--------------------------|---------------|-------------------------|------------|
| **Mouse**          |                          |               |                         |            |
| Asthma             | IL-25, IL-33, LTD4, TSLP, TLI1A | IL-4, IL-5, IL-9, IL-13, amphiregulin | AHR, eosinophilia, mucus production, tissue repair | [12, 13, 28, 33-37, 40, 49, 55, 56] |
| Atopic Dermatitis  | IL-33 TSLP               | IL-4, IL-5, IL-13 | orthokeratosis, acanthosis, skin lesions, eosinophilia | [38, 68, 69] |
| **Human**          |                          |               |                         |            |
| Asthma             | IL-25, IL-33, LXA4, PGD2, TSLP | IL-13 production from peripheral blood ILC2 | ? | [39, 49, 57-62] |
| Atopic Dermatitis  | IL-33 TSLP               | ?             | ?                       | [38, 69, 71] |
| Chronic Rhinosinusitis | IL-33 TSLP            | IL-13        | ?                       | [18, 23, 64, 65] |
ICOS has also been shown to be expressed by ILC2 and recently, a report of a Sca-1 that induced B1 B cells to produce IgA antibody does not support a robust pathway where ILC2 present antigen to CD4+ T cells.

ICOS was initially described to produce IL-6 and IL-13 after stimulation with TSLP and leukotriene D4, and thus could lead to interactions with ICOS-ligand expressing B cells [5].

A recent report also demonstrated that ILC2 are co-localized with mast cells in the dermis [68]. The authors tracked the movements of ILC2s using intravitreal multiphoton microscopy and found that interactions between mast cells and ILC2 lasted as long 30 minutes. Interestingly, the authors also found that IL-9 enhanced mast cell release of IL-6 and TNFα, while IL-13 had the opposite effect and suppressed mast cell release of IL-6 and TNFα. Another report demonstrated the presence of ILC2 in close proximity to mast cells in human lung, supporting potential ILC2/mast cell interactions [39]. The interactions between ILC2 and mast cells could have important influences on shaping allergic responses as mast cell mediators including PGD2 and leukotrienes can activate ILC2 and mast cells could be reciprocally modulated by ILC2 cytokines.

**SUMMARY**

The classic paradigm underlying allergic disease has been characterized by allergen specific Th2 cell production of IL-4, IL-5 and IL-13 leading to tissue eosinophilia, mucus production, and specific IgE production. Though the Th2 adaptive response to allergen exposure is well substantiated, recent evidence suggests that ILC2 may also contribute to pathogenic allergic inflammation. The evolutionary advantage of tissue ILC2 likely stems from an important early role in anti-parasitic immunity. In 2010, the identification of nuocytes, innate helper type 2 cells and natural helper cells as major players in type 2 immunity during helminth infections has led to investigations into ILC2 in allergic disease. ILC2, like other innate cells, do not require antigen experience and peripheral differentiation and thus could drive innate type 2 responses to viruses, tobacco smoke, and pollutants associated with asthma. Many important questions regarding the role of ILC2 in allergic diseases remain including how ILC2 contribute to ongoing allergic inflammation in the presence of intact adaptive immunity or how ILC2 can be specifically targeted therapeutically. Future studies aimed at addressing these questions will provide significant insight into mechanisms of ILC2 biology and their contributions to human disease.

**ABBREVIATIONS**

| Abbreviation | Definition |
|--------------|------------|
| AHR          | Airway hyperresponsiveness |
| CRTH2        | Chemoattractant receptor homologous molecule expressed on TH2 lymphocytes |
| DR3          | Death receptor 3 |
| EGFR         | Epidermal growth factor receptor |
| GATA3        | Transacting T cell specific transcription factor 3 |
| ICOS         | Inducible T-cell Costimulator |
| IgA          | Immunoglobulin A |
| IgE          | Immunoglobulin E |
| ILC2s        | Type 2 innate lymphoid cells |
| PGD2         | Prostaglandin D2 |
| STAT6        | Signal transducer and activator of transcription 6 |
CONFLICT OF INTEREST

The authors report no conflict of interest in the preparation of this manuscript.

ACKNOWLEDGEMENTS

Grant support: T.A.D. is supported by NIH grant 1K08AI080938 and ALA/AAAAI Allergic Respiratory Diseases Award.

REFERENCES

[1] Busse WW, Lemanske RF, Jr. Asthma. N Engl J Med 2001; 344(5): 350-62.
[2] Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15(6): 985-95.
[3] Hurst SD, Muchamuel T, Gorman DM, et al. New IL-17 family members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine IL-25. J Immunol 2002; 169(1): 443-53.
[4] Fallon PG, Ballantyne SJ, Mangan NE, et al. IL-25 and IL-33 promote Th2 responses in the lung. J Immunol 2006; 177(3): 1150-6.
[5] Neilr DR, Wong SH, Bellosi A, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464(7293): 1367-70.
[6] Price AE, Liang HE, Sullivan BM, et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010; 107(25): 11489-94.
[7] Moro K, Yamada T, Tanabe M, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature 2010; 463(7280): 540-4.
[8] Spits H, Artsis D, Colonna M, et al. Innate lymphoid cells—a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13(2): 145-9.
[9] Yang Q, Saenz SA, Zlotoff DA, Artsis D, Bhandoola A. Cutting edge: natural helper cells derive from lymphoid progenitors. J Immunol 2011; 187(11): 5505-9.
[10] Yokota Y, Mansouri A, Mori S, et al. Development of peripheral lymphoid organs and natural killer cells depends on the helios-loop-helix inhibitor Id2. Nature 1999; 397(6721): 702-6.
[11] Salot-Takayama N, Lesjorg-Petit S, Vieira P, Sawada S, Eberl G, Vossenrich CJ, et al. IL-7 and IL-15 independently program the differentiation of intestinal CD3-NKp46+ cell subsets from Id2-dependent precursors. J Exp Med 2010; 207(2): 273-80.
[12] Bartemes KR, Iijima K, Kobayashi T, Kephart GM, McKenzie AN, Kita H. IL-33-responsive lineage-CD25+CD44(hi) lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188(3): 1503-13.
[13] Doherty TA, Khorrarn N, Chang JE, et al. STAT6 regulates natural helper cell proliferation during lung inflammation initiated by Alternaria. Am J Physiol Lung Cell Mol Physiol. 2012; 303(7): L577-88.
[14] Wong SH, Walker JA, Jolin HE, et al. Transcription factor RORalpha is critical for nuocyte development. Nat Immunol 2012; 13(3): 229-36.
[15] Gentek R, Munneke JM, Helbig C, et al. Modulation of Signal Strength Switches Notch from an Inducer of T Cells to an Inducer of ILC2. Front Immunol 2013; 4: 334.
[16] Mielek LA, Groom JR, Rankin LC, et al. TCF-1 Controls ILC2 and NKp46+ RORgammat+ Innate Lymphocyte Differentiation and Protection in Intestinal Inflammation. J Immunol 2013; 191(8): 4383-91.
[17] Halim TY, MacLaren A, Romanish MT, Gold MJ, McNagny KM, Takei F. Retinoic-acid-receptor-related orphan nuclear receptor alpha is required for natural helper cell development and allergic inflammation. Immunity 2012; 37(3): 463-74.
[18] Mjosberg J, Bemink J, Golebski K, et al. The Transcription Factor GATA3 Is Essential for the Function of Human Type 2 Innate Lymphoid Cells. Immunity. 2012; 37(4): 649-59.
[19] Klein Wolterink RG, Serafini N, van Nimmegen M, et al. Essential, dose-dependent role for the transcription factor GATA3 in the development of IL-5+ and IL-13+ type 2 innate lymphoid cells. Proc Natl Acad Sci USA 2013; 110(25): 10240-5.
[20] Hoyer L, Klose CS, Souabni A, et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity. 2012; 37(4): 634-48.
[21] Shinnakasu R, Yamashita M, Kuwahara M, et al. Gfi1-mediated stabilization of GATA3 protein is required for Th2 cell differentiation. J Biol Chem 2008; 283(42): 28216-25.
[22] Sponent CJ, Lesch J, Yan D, et al. Specification of type 2 innate lymphocytes by the transcriptional determinant Gfi1. Nat Immunol 2013; 14(12): 1229-36.
[23] Mjosberg J, Trifari S, Crellin NK, et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTC2 and CD161. Nat Immunol 2011; 12(11): 1055-62.
[24] Saenz SA, Siracusa MC, Perrigoue JG, et al. IL-25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010; 464(7293): 1362-6.
[25] Saenz SA, Siracusa MC, Monticelli LA, et al. IL-25 simultaneously elicits distinct populations of innate lymphoid cells and multipotent progenitor type 2 (MPPtype2) cells. J Exp Med 2013; 210(9): 1823-37.
[26] Cu G, Wu L, Li X, et al. IL-17 family: Cytokines, receptors and signaling. Cytokine. 2013; 64(2): 477-85.
[27] Lloyd CM. IL-33 family members and asthma: bridging innate and adaptive immune responses. Curr Opin Immunol 2010; 22(6): 800-6.
[28] Chang YJ, Kim HY, Albacker LA, et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011; 12(7): 651-8.
[29] Kouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H. The Danger Signal, Extracellular ATP, Is a Sensor for an Airborne Allergen and Triggers IL-33 Release and Innate Th2-Type Responses. J Immunol 2011; 186(7): 4735-87.
[30] Tamachi T, Maesawa Y, Ikeda K, et al. IL-25 enhances allergic airway inflammation by amplyfing a TH2-cell-dependent pathway in mice. J Allergy Clin Immunol 2006; 118(3): 606-14.
[31] Angkasewinai P, Park H, Wang YH, et al. Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp Med 2007; 204(7): 1509-17.
[32] Doherty TA, Khorrarn N, Sugimoto K, et al. Alternaria Induces STAT6-Dependent Acute Airway Eosinophilia and Epithelial FIZZ1 Expression That Promotes Airway Fibrosis and Epithelial Thickness. J Immunol 2012; 188(6): 2622-9.
[33] Barlow JL, Peel S, Fox J, et al. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J Allergy Clin Immunol 2013; 132(4): 933-41.
[34] Chu DK, Llop-Guevara A, Walker TD, et al. IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. J Allergy Clin Immunol 2013; 131(1): 187-200 e1-8.
[35] Itø T, Wang YH, Duramad O, et al. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J Exp Med 2005; 202(9): 1213-23.
[36] Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP in the development of inflammation in an asthma model. J Exp Med 2005; 202(6): 829-39.
[37] Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of TH2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012; 36(3): 451-63.
[38] Kim BS, Siracusa MC, Saenz SA, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 2013; 5(170): 170ra16.
[39] Barning C, Cernadas M, Dutile S, et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med 2013; 5(174): 174ra26.
[40] Doherty TA, Khorrarn N, Lund S, Mehta AK, Croft M, Brodie DH. Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol 2013; 132(1): 205-13.
[41] Boyce JA. Mast cells and eicosanoid mediators: a system of reciprocal paracrine and autocrine regulation. Immunol Rev 2007; 217: 168-85.
Type 2 Innate Lymphoid Cells in Allergic Disease

[42] Chang JE, Doherty TA, Baum R, Broide D. Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis. J Allergy Clin Immunol 2014; 133(3): 899-901.

[43] Meylan F, Richard AC, Siegel RM. TL1A and DR3, a TNF family ligand-receptor pair that promotes lymphocyte costimulation, mucosal hyperplasia, and autoimmune inflammation. Immunol Rev 2011; 244(1): 188-96.

[44] Meylan F, Davidson TS, Kahle E, et al. The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. Immunity 2008; 29(1): 79-89.

[45] Yu X, Pappu R, Ramirez-Carrozzi V, et al. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol 2013 Nov 13; doi: 10.1038/mi.2013.92.

[46] Turner JE, Morrison PJ, Wilhelm C, et al. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminth-induced lung inflammation. J Exp Med 2013 Nov 18. [Epub ahead of print]

[47] Kurowska-Stolarska M, Kewin P, Murphy G, et al. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J Immunol 2008; 181(7): 4780-90.

[48] Nussbaum JC, Van Dyken SJ, von Moltke J, et al. Type 2 innate lymphoid cells control eosinophil homeostasis. Nature 2013; 502(7470): 245-8.

[49] Monticelli LA, Sonnenberg GF, Abt MC, et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12(11): 1045-54.

[50] Wilhelm C, Hirota K, Stiegltz B, et al. An IL-9-fate reporter demonstrates the induction of an innate IL-9 response in lung inflammation. Nat Immunol 2011; 12(11): 1071-7.

[51] Soroosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127(4): 450-8.

[52] Bando JK, Nussbaum JC, Liang HE, Locksley RM. Type 2 innate lymphoid cells constitutively express arginase-1 in the naive and inflamed lung. J Leukoc Biol 2013; 94(5): 877-84.

[53] Kim BS, Wojno ED, Artis D. Innate lymphoid cells and allergic inflammation. Curr Opin Immunol. 2013 Aug 31. doi: 10.1016/j.coi.2013.07.013.

[54] Klein Wolterink RG, Hendriks RW. Type 2 innate lymphocytes in allergic airway inflammation. Curr Allergy Asthma Rep 2013; 13(3): 271-80.

[55] Barlow JL, Bellosi A, Hardman CS, et al. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012; 129(1): 191-8 e1-4.

[56] Klein Wolterink RG, Kleinjan A, van Nimwegen M, et al. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012; 42(5): 1106-16.

[57] Fajt ML, Gelhaus SL, Freeman B, et al. Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol 2013; 131(6): 1504-12.

[58] Prefontaine D, Lajoie-Kadoch S, Foley S, et al. Increased expression of IL-33 in severe asthma: evidence of expression by airway smooth muscle cells. J Immunol 2009; 183(8): 5094-103.

[59] Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med 2001; 164(2): 277-81.

[60] Corrigan CJ, Wang W, Meng Q, et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J Allergy Clin Immunol 2011; 128(1): 116-24.

[61] Ying S, O’Connor B, Ratoff J, et al. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J Immunol 2005; 174(12): 8183-90.

[62] Allakverdi Z, Comeau MR, Smith DE, et al. CD34+ hematopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009; 123(2): 472-8.

[63] Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.

[64] Shaw JL, Fakhti S, Citardi MJ, et al. IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2013; 188(4): 432-9.

[65] Nagarkar D. Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis. J Allergy Clin Immunol 2013; 132(3): 593-600.

[66] Akdis CA, Bachert C, Cingi C, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2013; 131(6): 1479-90.

[67] Van Zele T, Claeyts S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 2006; 61(11): 1280-9.

[68] Roediger B, Kyle R, Yip KH, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. Nat Immunol 2013; 14(6): 564-73.

[69] Imai Y, Yasuda K, Sakaguchi Y, et al. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 2013; 110(34): 13921-6.

[70] Soumelis V, Reche PA, Kanzler H, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002; 3(7): 673-80.

[71] Savinco T, Matikainen S, Saarialho Kere U, et al. IL-33 and ST2 in atopic dermatitis: expression profiles and modulation by triggering factors. J Invest Dermatol 2012; 132(5): 1392-400.

[72] Barrett NA, Rahman OM, Fernandez JM, et al. Dectin-2 mediates Th2 immunity through the generation of cytokine leukotrienes. J Exp Med 2011; 208(3): 593-604.

[73] Fukuoka A, Futatsugi-Yumikura S, Takahashi S, et al. Identification of a novel type 2 innate immune cell with the ability to enhance IgE production. Int Immunol 2013; 25(6): 373-82.